Preparation method and application of sulfydryl-activated lenalidomide anticancer diagnosis and treatment prodrug

The thiol-activated lenalidomide-based prodrug Lena-green addresses the challenge of targeting tumor sites by selectively responding to high thiol concentrations, achieving efficient drug release and cytotoxicity in cancer cells.

CN119080757AActive Publication Date: 2024-12-06LANZHOU UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411126219.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-12-06
Estimated Expiration
2044-08-16

AI Technical Summary

Technical Problem

Existing diagnostic and therapeutic strategies for cancer lack specificity and efficiency in targeting tumor sites, particularly in utilizing the unique microenvironment of cancer cells to enhance drug concentration and visualization.

Method used

A thiol-activated lenalidomide-based anticancer prodrug, Lena-green, is synthesized to selectively respond to the high thiol concentration in tumor tissues, releasing active drugs and fluorescent imaging agents for targeted therapy.

Benefits of technology

The prodrug demonstrates high specificity and efficiency in tumor site activation, achieving drug release efficiencies up to 98% and effective cytotoxicity against cancer cells, with minimal interference from non-tumor thiols.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080757A_ABST
    Figure CN119080757A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses a preparation method and application of a biological sulfydryl-activatable anticancer diagnosis and treatment prodrug molecule. A BH derivative skeleton with a fluorophore is connected with lenalidomide to obtain a diagnosis and treatment prodrug which releases a lenalidomide drug and the fluorophore after being activated by biological sulfydryl. After the diagnosis and treatment prodrug molecule disclosed by the invention acts with high-expression biological sulfydryl in tumor cells, anti-cancer drug molecules are released, so that the aim of targeted treatment of cancers is fulfilled.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of organic synthesis and molecular medicine, and in particular to a preparation method and use of a thiol-activated lenalidomide anti-cancer diagnostic and therapeutic prodrug. Background Art

[0002] The development of diagnostic and therapeutic strategies can be used to diagnose early cancer, provide therapeutic drugs for tumors and visualize the cancer stage, and provide more effective and personalized treatment for cancer patients. Diagnostic and therapeutic prodrugs usually consist of four parts, including: drug molecules, signal output units, trigger response units, and connection sites. The activation of small molecule diagnostic and therapeutic agents is generally achieved by breaking chemical bonds through the difference between the tumor tissue microenvironment and normal tissue, releasing the original drug molecules and fluorescent imaging molecules, so as to achieve the purpose of exerting diagnostic and therapeutic effects. The tumor microenvironment mainly includes high biological thiol concentration, high reactive oxygen level, low pH value, unique enzyme activity, etc. Therefore, the stimulus response drugs induced by the tumor microenvironment can significantly enhance the efficacy of anticancer drugs by increasing the drug concentration at the tumor site. Based on this, the present invention discloses a thiol-activated new diagnostic and therapeutic prodrug based on lenalidomide to achieve the purpose of targeted cancer therapy. Summary of the invention

[0003] The present invention discloses a new strategy to provide an anticancer prodrug molecule, which has a simple structure, is easy to obtain, is convenient to synthesize, has a good tumor treatment effect, and has a high application value. In addition, the present invention provides a method for preparing an anticancer prodrug molecule by connecting an anticancer active molecule with a BH derivative skeleton, with a high reaction yield and good purity. BRIEF DESCRIPTION OF THE DRAWINGS

[0004] Figure 1 This is a graph showing the ultraviolet absorption spectrum of the prodrug molecule Lena-green provided in Experimental Example 1 of the present invention after reacting with rBSA;

[0005] Figure 2 This is a graph showing the time-dependent fluorescence spectrum of the prodrug molecule Lena-green provided in Experimental Example 1 of the present invention after the prodrug molecule Lena-green reacts with rBSA;

[0006] Figure 3 This is a diagram showing the selective test results of the prodrug molecule Lena-green provided in Experimental Example 1 of the present invention;

[0007] Figure 4 This is a graph showing the HPLC results of the reaction between the prodrug molecule Lena-green and rBSA in Experimental Example 1 of the present invention;

[0008] Figure 5This is a graph showing the toxicity results of the prodrug molecule Lena-green and the parent drug molecule (Lena) to HeLa cells provided in Experimental Example 1 of the present invention;

[0009] Figure 6 This is a cell fluorescence imaging image of the prodrug molecule Lena-green provided in Experimental Example 1 of the present invention in HeLa cells;

[0010] Example 1

[0011] The present invention discloses a novel diagnostic and therapeutic prodrug molecule based on lenalidomide, the structural formula of which is:

[0012]

[0013] The synthetic route of the novel diagnostic and therapeutic prodrug molecule based on lenalidomide described in the present invention is as follows:

[0014]

[0015] The method for preparing the novel diagnostic and therapeutic prodrug molecule based on lenalidomide of the present invention is as follows:

[0016] Synthesis of compound S1: 4-diethylaminosalicylaldehyde (5 g, 26 mmol) was dissolved in 100 mL of n-butanol, and ethyl nitroacetate (3.0 mL, 26 mmol) was added, followed by piperidine (0.5 mL) and acetic acid (1.1 mL). The reaction solution was refluxed at 120 °C for 24 hours, and then cooled in an ice-water bath for crystallization. The precipitate was collected by filtration, the filter cake was washed with ice petroleum ether, and dried to obtain compound S1 as an orange-red needle-shaped solid.

[0017] Synthesis of compound S2: Compound S1 (5 g, 19 mmol) and stannous chloride (25.5 g, 113 mmol) were added to a 250 mL round-bottom flask, 90 mL of ethanol was added, concentrated hydrochloric acid (45 mL) was slowly added dropwise in an ice-water bath, stirred at room temperature, and the reaction was monitored by TLC. After the reaction was completed, 200 mL of ice water was prepared three times, NaOH powder was added, and the reaction solution was slowly added three times. After standing for a period of time, a yellow precipitate was precipitated, filtered, and dried. Then column chromatography was performed to purify the yellow solid compound S2.

[0018] Synthesis of compound S3: Compound S2 (192 mg, 0.83 mmol) and triethylamine (0.12 mL, 0.86 mmol) were dissolved in dry dichloromethane (10 mL) at room temperature, and then acryloyl chloride (0.14 mL, 1.66 mmol) was added at 0°C under argon protection. After stirring at room temperature for 6 hours, the reaction mixture was diluted with dichloromethane. Then, saturated NaHCO 3 Wash with aqueous solution and use anhydrous Na 2SO 4 The residue was dried and concentrated to remove the solvent and purified by chromatography (PE / EA=4 / 1) to obtain compound S3 as a light yellow solid.

[0019] Synthesis of compound S4: Under argon protection, a mixed solution of compound S3 (60 mg, 0.2 mmol), paraformaldehyde (44 mL, 0.6 mmol), 1,4-diazabicyclo[2.2.2]octane (DABCO) (12 mg, 0.1 mmol) and 9 mL of acetonitrile was stirred at 50 °C for 24 h. The mixture was then diluted with 150 mL of water and washed with NaHCO 3 The solid was neutralized, then extracted with ethyl acetate and separated. The organic layer was washed with Na 2 SO 4 After drying and filtering, the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography (PE / EA=3 / 1) to give compound S4 as a yellow solid.

[0020] Synthesis of Lena-green: Dissolve triphosgene (30 mg, 0.1 mmol), lenalidomide (65 mg, 0.25 mmol) and triethylamine (41 mL, 0.3 mmol) in 4 mL of dichloromethane, and heat the reaction solution at 45 ° C for 2 hours to obtain an intermediate. Then add compound S4 (63 mg, 0.2 mmol) and triethylamine (41 mL, 0.3 mmol) to react for 20 minutes. The product was collected by column chromatography (DCM / MeOH=200 / 1-50 / 1) to obtain a yellow solid compound Lena-green. 1H NMR (400 MHz, CDCl 3)d:9.05(s,1H),8.57(s,1H),8.45(s,1H),7.84(d,J=8.0Hz,1H),7.64(d,J=7.5Hz,1H),7.55(s, 1H),7.46(t,J=7.8Hz,1H),7.28(d,J=8.8Hz,1H),6.60(d,J=8.3Hz,1H),6.46(s,1H),6.28(s,1H) ,5.81(s,1H),5.21(dd,J=13.2,5.2Hz,1H),5.00(d,J=4.7Hz,2H),4.45(d,J=4.2Hz,2H),3.40(q ,J=7.1Hz,4H),2.85(s,2H),2.40(dd,J=12.9,5.3Hz,1H),2.22(s,1H),1.20(t,J=7.0Hz,6H).13C NMR(101MHz, CDCl3)d:171.31,169.75,169.00,164.10,160.09,152.78,149.77,137.55,132.62,132.57,129.36,128 .93,126.90,120.21,118.45,109.87,108.06,97.20,65.16,51.84,50.88,45.92,44.77,31.54,29.71,23.32,12.47.

[0021] Experimental Example 2

[0022] This experimental example provides the UV absorption spectrum results after the prodrug molecule Lena-green reacts with rBSA;

[0023] Experimental method: The stock solution of prodrug Lena-green was prepared by DMSO, and the final test compound concentration was 2 μM. The ultraviolet absorption of Lena-green (2 μM) and rBSA (2 μM) before and after the reaction was tested by ultraviolet spectrophotometer, and the following was obtained: Figure 1 Results shown.

[0024] Experimental results: Figure 1 As shown, the maximum absorption wavelength of the prodrug Lena-green is at 415nm. When 2mM rBSA is added to the prodrug for 2 hours, the maximum absorption wavelength blue-shifts to 400nm. The experimental results show that the prodrug Lena-green has a certain response to rBSA.

[0025] Experimental Example 3

[0026] This experimental example provides the time-dependent results of the fluorescence spectrum after the prodrug molecule Lena-green interacts with rBSA;

[0027] Experimental method: The maximum excitation wavelength of the prodrug molecule Lena-green is 410nm. The prodrug molecule Lena-green (2μM) and rBSA (2μM) were tested for time-dependent fluorescence spectroscopy at 37°C using a fluorescence spectrophotometer.

[0028] Experimental results: Figure 2 As shown, under the excitation wavelength of 410 nm, Lena-green has a weak fluorescence intensity at 490 nm. After adding 2 mM rBSA, the fluorescence intensity gradually increases with the action time.

[0029] Experimental Example 4

[0030] This experimental example provides the results of the selective testing of the prodrug molecule Lena-green;

[0031] Experimental method: The prodrug molecule Lena-green (2 μM) was incubated with other interfering substances for a certain period of time and then its fluorescence signal was tested ( Figure 3 The interfering substances given in the experiment are 1, blank; 2, GSH; 3, Hcy; 4, Cys; 5, E-Trx; 6, reduced E-Trx; 7, lysozyme; 8, reduced lysozyme; 9, BSA; 10, rBSA). The specific experimental results are shown in Figure 3 shown.

[0032] Experimental results: When the prodrug Lena-green was incubated with 100 times the amount of small molecule thiols for 90 minutes, there was almost no fluorescence release. After incubating it with proteins that did not contain vicinal dithiols after oxidation for 90 minutes, there was no obvious fluorescence enhancement. However, after incubating Lena-green with proteins containing vicinal dithiols for 90 minutes, the fluorescence intensity was significantly enhanced by more than 20 times, indicating that the prodrug Lena-green can specifically respond to vicinal dithiols proteins without being affected by other biological thiols.

[0033] Experimental Example 5

[0034] This experimental example provides the HPLC results of the reaction between the prodrug molecule Lena-green and rBSA;

[0035] Experimental method: Lena-green (20mM), Lena (20mM), and rBSA (20mM) were tested in PBS buffer at 37°C. Lena-green and rBSA were incubated in PBS buffer for a specified time and then analyzed by HPLC for the content of Lena in the solution. The results are shown in Table 1. Figure 4 shown.

[0036] Experimental results: rBSA (20mM) was added to the prodrug Lena-green (20mM) for incubation. As the incubation time increased, the chromatographic peak of Lena-green decreased significantly, and the chromatographic peak of Lena appeared at a retention time of about 4.7 minutes. When the visualized prodrug Lena-green was incubated with rBSA for 60 minutes, the drug release efficiency reached 88%. After incubation for 120 minutes, the drug release efficiency was as high as 98%.

[0037] Experimental Example 6

[0038] This experimental example provides the toxicity results of the prodrug molecule Lena-green and the parent drug molecule (Lena) on HeLa cells;

[0039] Experimental method: Hela cells were evenly inoculated into 96-well plates, and 2.5×10 3 After the cells adhered overnight, different concentrations of Lena and Lena-green were added. The cells were incubated in a cell culture incubator for 72 hours, and then 10 mL of CCK-8 solution was added to each well. The cells were incubated in a cell culture incubator for another 4 hours, and then the absorption at 450 nm was detected using an ELISA reader.

[0040] Experimental results: From Figure 5 It can be seen that the prodrug Lena-green has a similar cytotoxicity to Lena at low concentrations. However, when its concentration increased from 12.5mM to 25mM, the cell viability decreased significantly from 70% to about 30%. It also showed a strong cell viability inhibition effect at subsequent high concentrations.

[0041] Experimental Example 7

[0042] This experimental example provides cell fluorescence imaging of the prodrug molecule Lena-green in HeLa cells;

[0043] Experimental method: HeLa cells were evenly seeded into 12-well plates, and 2×10 4 cells at 37°C and 5% CO 2 Cultured overnight in an incubator until the cells were completely attached, then 30 mM PAO inhibitor (a commonly used protein vicinal dithiol blocking agent) or 10 mM Lena-green was added and incubated for the corresponding time. After washing three times with PBS, fluorescence imaging was performed using a fluorescence microscope.

[0044] Experimental results: Figure 6As shown, the control group had almost no fluorescence. After incubating HeLa cells with the prodrug molecule Lena-green, bright green fluorescence can be seen under a fluorescence microscope. After using PAO to inhibit the content of reduced vicinal dithiol proteins in the cells, and then incubating them with Lena-green, it can be clearly seen that the fluorescence in the cells is significantly reduced, proving that Lena-green can be specifically activated by endogenous vicinal dithiol proteins in the cells.

Claims

1. An anti-cancer diagnostic and therapeutic prodrug molecule, characterized in that: Its structural formula is:

2. The anticancer diagnostic and therapeutic prodrug molecule according to claim 1, characterized in that Coumarin was used as the fluorescent reporter group and lenalidomide as the active drug molecule.

3. Use of the lenalidomide prodrug molecule as claimed in claim 1 or 2 in the preparation of anticancer prodrug molecules.

4. A method for preparing an anticancer prodrug molecule, characterized in that: include: The active drug molecule lenalidomide as claimed in claim 1 or 2 is connected to the BH derivative skeleton through a condensation reaction to obtain the anticancer prodrug molecule.

Citation Information

Patent Citations

  • Coumarin-3-formamide derivative, preparation method thereof and application of coumarin-3-formamide derivative in preparation of antitumor drugs

    CN117164572A

  • Isoindolinone derivative with glutarimide parent nucleus and application thereof

    CN118234721A

  • Heterobifunctional compositions for targeted protein degradation and methods for their use

    WO2022187650A1